Peer-reviewed veterinary case report
How thyroid stimulating hormone affects radioactive iodine uptake
By Scheemaeker, Stephanie et al.·Published in Journal of veterinary internal medicine·2024·Small Animal Department·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of recombinant human thyroid stimulating hormone on radioactive iodine uptake by thyroid carcinoma in dogs.
- Species:
- dog
Plain-English summary
A group of nine dogs with thyroid cancer received a treatment that included a hormone called recombinant human thyroid stimulating hormone (rhTSH) to see if it would help their tumors absorb more radioactive iodine during therapy. The results showed that the dogs had a significantly higher uptake of radioactive iodine 24 hours after receiving rhTSH compared to when they did not receive it. This suggests that using rhTSH can improve the effectiveness of radioactive iodine treatment for dogs with thyroid cancer. The dogs were monitored for changes in thyroid hormone levels, which also showed positive results after the treatment.
People also search for: dog thyroid cancer treatment · radioactive iodine therapy for dogs · rhTSH for dog cancer
Abstract
BACKGROUND: The high doses of radioiodine-131 (I) and, subsequently, the high radioactive burden for dog and environment warrants optimization ofI therapy in dogs with thyroid carcinoma (TC). HYPOTHESIS/OBJECTIVES: To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC. ANIMALS: Nine client-owned dogs diagnosed with TC. METHODS: A prospective cross-over study in which tumor RAIU was calculated and compared at 8 hours (8h-RAIU) and 24 hours (24h-RAIU) after injection of radioactive iodine-123 (I), once with and once without rhTSH (ie, 250 μg, IM, 24 and 12 hours beforeI) in each dog. Simultaneously, serum total thyroxine (TT4) and TSH were measured at baseline (T), and 6 (T), 12 (T), 24 (T), and 48 hours (T) after the first rhTSH administration. RESULTS: Tumor RAIU was significantly higher at 24 hours with rhTSH compared to no rhTSH (mean difference = 8.85%, 95% CI of [1.56; 16.14]; P = .03), while this was non-significant at 8 hours (mean difference = 4.54%, 95% CI of [0.35; 8.73]; P = .05). A significant change of serum TT4 (median difference T - T = 35.86 nmol/L, interquartile range [IQR] = 15.74 nmol/L) and TSH (median difference T - T = 1.20 ng/mL, IQR = 1.55 ng/mL) concentrations occurred after administration of rhTSH (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Recombinant human TSH could optimizeI treatment in dogs with TC by increasing tumor RAIU and thusI treatment efficacy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39023205/